Eli Lilly signed a research and collaboration agreement with QurCan Therapeutics to develop CNS and peripheral nervous system therapeutics. The partnership targets diseases across nervous-system pathways, aligning with Lilly’s broader push to leverage platform know-how from metabolic and endocrine programs into neurobiology and immunologic mechanisms. The collaboration adds another external innovation engine for Lilly as the company keeps building around biologic discovery and translational neuroscience programs. Near-term milestones and the division of labor between lead optimization and preclinical package generation will likely determine whether the deal becomes a pipeline contributor or remains a discovery-stage option.